Literature DB >> 14764676

Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status.

Nazik Rayman1, King H Lam, Jon D Laman, Peter J Simons, Bob Löwenberg, Pieter Sonneveld, Ruud Delwel.   

Abstract

Using two distinct anti-CB2 receptor Abs, we investigated the expression patterns of the peripheral cannabinoid receptor CB2 in human secondary lymphoid organs. Immunohistochemical analysis using an N-terminal specific anti-CB2 Ab revealed high protein expression in the germinal centers (GCs) of secondary follicles. A C-terminal specific anti-CB2 Ab, which only recognizes a nonphosphorylated inactive receptor, showed positivity in the mantle zones (MZs) and marginal zones (MGZs) of the secondary follicles where resting cells reside, and in the primary follicles. In contrast, no positivity was observed in GCs using the C-terminal Ab, suggesting that active CB2 receptors are mainly present on cells in the GCs. Dual immunohistochemical analysis revealed that B lymphocytes express the CB2 protein abundantly. In contrast to B cells in the MZ or MGZ, CB2-expressing cells in the GCs coexpress the costimulatory membrane protein CD40, which is mainly expressed in the GCs and at very low levels in the MZs and MGZs and the proliferation marker Ki-67. Using the human Raji B cell line as a model, we demonstrate in a transwell assay that moderate migration occurs upon stimulation of the CB2 receptor with the endocannabinoid 2-arachidonoylglycerol, which is enhanced by CD40 costimulation. Our findings, that GC-related cells express active CB2 and that CB2-dependent migration requires CD40 costimulation, suggest that CB2 is involved in B cell activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764676     DOI: 10.4049/jimmunol.172.4.2111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

Review 2.  CB2 receptor-mediated migration of immune cells: it can go either way.

Authors:  A M Miller; N Stella
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

Review 3.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

4.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

5.  Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.

Authors:  L S Whyte; L Ford; S A Ridge; G A Cameron; M J Rogers; R A Ross
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

6.  Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation.

Authors:  Julie T Castaneda; Airi Harui; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-31       Impact factor: 4.147

Review 7.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

8.  2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells.

Authors:  Qing Zhao; Zhiwei He; Nanyue Chen; Yong-Yeon Cho; Feng Zhu; Chengrong Lu; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2005-05-10       Impact factor: 5.157

9.  Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.

Authors:  Pietro Marini; Maria-Grazia Cascio; Angela King; Roger G Pertwee; Ruth A Ross
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Identification of transcription start sites and preferential expression of select CB2 transcripts in mouse and human B lymphocytes.

Authors:  Tracy A Sherwood; Liang Nong; Marisela Agudelo; Cathy Newton; Ray Widen; Thomas W Klein
Journal:  J Neuroimmune Pharmacol       Date:  2009-09-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.